When will Napavir sodium (Sunlenca) be available in China?

Lenapavir sodium/Sunlenca (Sunlenca) has been officially approved for marketing by China’s National Medical Products Administration (NMPA) on December 25, 2024, with the trade name “Sunlenca”. The introduction of the drug is considered a major breakthrough in China's AIDS treatment system, marking my country's official entry into a new stage of long-acting HIV treatment. The dosage forms approved this time include oral tablets and injections, which are suitable for adult patients who require long-term viral suppression and have drug resistance or compliance issues.

At present, Salanka has not been included in the national medical insurance directory, and the price is relatively high. Most patients receive support through commercial insurance, assistance projects or import channels. However, from the perspective of policy trends, with the improvement of the HIV prevention and treatment system and the advancement of the localization of antiviral drugs, it is more likely to be included in medical insurance in the future. Gilead is also actively cooperating with relevant domestic institutions to promote the localization of the drug supply chain to reduce costs and expand accessibility.

Compared with traditional anti-HIV treatment regimens, the injection form of lenapavir sodium can achieve "six-monthly dosing", significantly improving patient compliance, which is especially significant for multi-drug resistant patient groups that require long-term management. Its launch further enriches the spectrum of HIV treatment drugs in China and complements drugs such as Biktarvy and Dolutegravir, providing more options for personalized treatment.

In addition, the introduction of lenapavir sodium has also had a positive impact on China's public health system. Its long-acting characteristics reduce the frequency of drug distribution and patient follow-up, reduce the burden on the medical system, and have practical significance for improving the quality of life of HIV-infected patients. In the future, with the accumulation of clinical experience and in-depth marketing promotion, Salanka is expected to become one of the indispensable core drugs in the management of HIV chronic diseases.

Reference materials:https://www.drugs.com/sunlenca.html